Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
0.6213(c) 0.65(c) 0.5999(c) 0.57(c) 0.58(c) Last
483 422 786 644 717 630 535 054 378 935 Volume
-1.68% +4.62% -7.71% -4.98% +1.75% Change
More quotes
Financials ($)
More Financials
Company
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
03/16 NAVIDEA BIOPHARMACEUTICALS : Completes Sale of North American Rights of Lymphose..
03/16 NAVIDEA BIOPHARMACEUTICALS : Research Reports Coverage on Biotech Stocks -- Inot..
03/13 NAVIDEA BIOPHARMACEUTICALS, INC. (NY : NAVB) Files An 8-K Departure of Directors..
03/13 NAVIDEA BIOPHARMACEUTICALS, INC. : Change in Directors or Principal Officers (fo..
03/09 NAVIDEA BIOPHARMACEUTICALS, INC. (NY : NAVB) Files An 8-K Entry into a Material ..
03/09 NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, T..
03/03 NAVIDEA BIOPHARMACEUTICALS : Completes Sale of North American Rights of Lymphose..
03/02 NAVIDEA BIOPHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security H..
02/23 NAVIDEA BIOPHARMACEUTICALS, INC. : Other Events (form 8-K)
02/17 NAVIDEA BIOPHARMACEUTICALS, INC. (NY : NAVB) Files An 8-K Other Events
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/02 Navidea shareholders OK sale of Lymphoseek sale to Cardinal; shares up 29%
02/23 Navidea settles dispute with debt holder for $59M; shares up 27%
02/23 Navidea trading halted pending news
2016 Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5%
2016 Trading in Navidea halted pending news
Advertisement
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mike M. Goldberg President, Chief Executive Officer & Director
Jed Andrew Latkin Chief Operating & Financial Officer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Tomblyn Chief Medical Officer & Senior Vice President
David Colborn Vice President-Clinical Operations
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTI..-9.02%90
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results